NLR and BRCA mutational status in patients with high grade serous advanced ovarian cancer

Claudia Marchetti; Marco D’Indinosante; Carolina Bottoni; Chiara Di Ilio; Stefano Di Berardino; Barbara Costantini; Angelo Minucci; Laura Vertechy; Giovanni Scambia; Anna Fagotti

doi:10.1038/s41598-021-90361-w

Scientific Reports (May 2021)

NLR and BRCA mutational status in patients with high grade serous advanced ovarian cancer

Claudia Marchetti,
Marco D’Indinosante,
Carolina Bottoni,
Chiara Di Ilio,
Stefano Di Berardino,
Barbara Costantini,
Angelo Minucci,
Laura Vertechy,
Giovanni Scambia,
Anna Fagotti

Affiliations

Claudia Marchetti: Department of Woman, Child and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS
Marco D’Indinosante: Department of Woman, Child and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS
Carolina Bottoni: Department of Woman, Child and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS
Chiara Di Ilio: Department of Woman, Child and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS
Stefano Di Berardino: Department of Woman, Child and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS
Barbara Costantini: Department of Woman, Child and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS
Angelo Minucci: Molecular and Genomic Diagnostics Laboratory, Fondazione Policlinico Universitario A. Gemelli IRCCS
Laura Vertechy: Department of Woman, Child and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS
Giovanni Scambia: Department of Woman, Child and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS
Anna Fagotti: Department of Woman, Child and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS

DOI: https://doi.org/10.1038/s41598-021-90361-w
Journal volume & issue: Vol. 11, no. 1
pp. 1 – 8

Abstract

Read online

Abstract Laboratory-markers of the systemic inflammatory-response, such as neutrophil/lymphocyte-ratio (NLR) have been studied as prognostic factors in several tumors but in OC-patients their role is still controversial and no data about the possible correlation with the BRCA-status has been ever reported. We consecutively enrolled a series of 397 newly diagnosed high-grade serous-advanced OC-patients. All patients were tested for BRCA-mutational-status and blood-parameters have been collected 48 h before staging-surgery. A significant correlation of NLR with disease distribution (p 4 (BRCA-mutated: 35 vs 23 months, p = 0.03; BRCA-wt: 19 vs 16 months, p = 0.05). At multivariate-analysis, independent factors of prolonged PFS were BRCA mutational status, having received complete cytoreduction and NLR < 4. Also, the strongest predictors of longer OS were BRCA-mutational status, having received complete cytoreductive surgery, NLR < 4 and age. NLR is confirmed to be a prognostic marker in OC-patients and it seems unrelated with BRCA-mutational status.

Published in Scientific Reports

ISSN: 2045-2322 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Medicine; Science
Website: https://www.nature.com/srep/

About the journal